Bill would extend ALS research law funding through 2031

What does this do?

This bill extends the Accelerating Access to Critical Therapies for ALS Act, pushing its expiration from 2026 to 2031 and continuing funding for ALS research grants. It also requires FDA checks on clinical trial progress before renewing grants, clarifies which trials qualify as "phase 3," and mandates a public FDA report on its 2022 ALS action plan along with an updated 5-year plan.

Who does it affect?

The bill affects ALS patients and families, medical researchers, and pharmaceutical companies developing ALS treatments. The FDA and GAO are also affected, as both oversee reporting and program review requirements.

Why does it matter?

Extending the law keeps existing grant funding mechanisms and FDA oversight processes in place for five additional years, while the added reporting requirements increase FDA's review and disclosure obligations.

What does it cost, and who pays?

• Grant funding continues through 2031
• No specific amounts specified